PVN MicroRNA in Sympathoexcitation balance. 22 However, the role of miR-7b and that of its regulation by the transcription factor Homeobox D10 (HoxD10) 23 in the PVN during CHF has not been studied. Furthermore, it has been reported that specific miRNAs play an integral role in AT 1 R signaling, especially after activation of the Gαq signaling pathway. 24 We hypothesize that during CHF, ANG II stimulates HoxD10-mediated miR-7b expression in the PVN, in turn contributing to elevated RSNA by inhibiting GABBR1 expression. To test this hypothesis, we infused, in a rat model of CHF, ANG II, adenoviral vectors containing rat AT 1 R siRNA (Ad-siAT 1 R), adenoviral vectors containing rat HoxD10 (Ad-HoxD10), miR-7b or an inhibitory antisense oligonucleotide, adenoviral vectors containing rat GABBR1 siRNA (Ad-siGABBR1) into the PVN, and we measured cardiac function, hemodynamic parameters, anatomic indicatiors, and sympathetic drive indicators. Furthermore, in vivo, we evaluated AT 1 R, HoxD10, miR-7b, and GABBR1 expression in the PVN of rats with CHF. In cultured NG108 cells treated with ANG II and the ANG II AT 1 R blocker losartan (Los), we determined HoxD10, miR-7b, and GABBR1 expression. In cultured HEK293 cells, we determined the binding of miR-7b to the 3′-UTR of GABBR1 gene.
Methods
An expanded methods section is available in the Data Supplement.
Animals
Male Wistar rats weighing between 180 and 200 g (Changchun Yisi Laboratory Animal Technology Company, Ltd, Changchun, China) were used to induce CHF by coronary ligation as previously described. 17 Catheters were inserted bilaterally into the PVN under anesthesia using stereotaxic technique. 25 Drugs were infused using minipumps at doses based on preliminary experiments and previous studies. [26] [27] [28] Six weeks after coronary ligation, cardiac function was measured using echocardiography under anesthesia providing left ventricular diastolic and systolic diameter, ejection fraction (EF), and fractional shortening (FS). 29 In addition, the rats were anaesthetized and prepared for determination of mean arterial blood pressure (MAP), heart rate (HR), left ventricular end diastolic pressure (LVEDP), left ventricular end systolic pressure, maximum first differentiation of left ventricle pressure (dP/dt max ), and RSNA as described previously. 26 After the experiment, tissue was harvested for further analysis.
Four separate groups of animals were used to study the effect of AT 1 R inhibition with Los on the protein expression of HoxD10 and GABBR1 and quantitative polymerase chain reaction for miR-7b (n=6 for each group): sham-operated control (Sham)+vehicle (Veh), Sham+Los, CHF+Veh, and CHF+Los. Two weeks following coronary artery ligation, 2 subgroups of rats (Los-treated sham and Lostreated CHF) were treated with 10 mg/kg/d Los (Merck, Whitehouse Station, NJ) in the drinking water for 4 weeks before killing. All animals received humane care in compliance with Institutional Animal Care and Use Committees of Jilin Normal University, Zhejiang University, Georgetown University, and Uppsala University. Use of animals in this study was confirmed with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (the 8th Edition).
Gene Silencing and Transferring In Vivo
Recombinant adenoviral vectors (1×10 9 plaque-forming units/mL) harboring rat AT 1 R siRNA (Ad-siAT 1 R, GenBank accession No. NM74054), rat HoxD10 (Ad-HoxD10, GenBank accession No. NM_001107094), rat GABBR1 siRNA (Ad-siGABBR1, GenBank accession No. NM_031028), or green fluorescent protein siRNA (Ad-siGFP) were manufactured by Vector Gene Technology Company Ltd (Beijing, China). Corresponding virus with null content (Ad-null) or Ad-siGFP was used as a control. To achieve stable knockdown of AT 1 R or GABBR1 in the PVN, we used adenoviral vectors expressing siRNA targeted against AT 1 R or control message (GFP), which were constructed and purified. Briefly, 21 base-pair short hairpin RNA targeting sequences specific for AT 1 R, GABBR1 or GFP were engineered under the control of the rat U6 promoter. The hairpin was situated next to the U6 transcription start site (within 6 base pairs) and followed by a synthetic, minimal polyA cassette. PVN infusions were performed 4 weeks before subsequent procedures to ensure robust transgene expression.
ANG II Infusion
After coronary ligation or sham operation, each rat was anesthetized (60 mg/kg ketamine+5 mg/kg xylazine IP) and underwent subcutaneous implantation of osmotic mini pumps (Alzet Model No1004). The pumps were connected to bilateral PVN cannulae for continuous infusion (0.11 μL/h/side) of antagomiR-7b or Ad-siGABBR1 at a total dose of 40 ng/h, NC antagomiR or Ad-siGFP, over a 4-week treatment period. Then the mini pump (Alzet Model No1004) was replaced by another mini pump (Alzet Model No1002). Alzet Model No1002 mini pump were connected to the bilateral PVN cannula for continuous infusion (0.25 μL/h/side) of ANG II at a total dose of 1 ng/kg per min, over a 2-week treatment period.
Tissue
Plasma was collected for measuring norepinephrine (NE). Heart tissue was used to measure infarction size as previously described. 17 Brain sections were stored for histology, and PVN samples were isolated using a micropunch technique. 30, 31 
In Vitro Analysis
The concentration of NE in the plasma and ANG II in the PVN was quantified using an ELISA kit (Rocky Mountain Diagnostics, Colorado Spring, CO) and performed according to the manufacturer's instructions. 28, 32, 33 Histological analysis of PVN infusion sites and fluorescence determination of agomiR-7b and antagomiR-7b were performed by standard techniques. 34 Fra-like (Fra-LI) expression was determined by immunohistochemistry to assess neuronal activation in the PVN. 35 GABBR1 immunofluorescence was determined by standard techniques using an anti-GABBR1 antibody (Novus Biologicals, Littletown). Western blot for the transcription factor HoxD10 was performed on nuclear protein extract as previously described. 36, 37 RNA was extracted from PVN micropunches or cultured cells as described in the Data Supplement. Real-time reverse transcriptase polymerase chain reaction quantification of miR-7b level and Western blot analysis for GABBR1 expression were performed by standard techniques (see Data Supplement).
Synthesis of AgomiRs and miRNA Inhibitor AntagomiRs
The mature miRNA agomiR-7b and its antisense inhibitor an-tagomiR-7b were synthesized by GenePharma (Shanghai, China).
Mutagenesis
Nucleotide-substitution mutations were performed using polymerase chain reaction-based methods for the 3′-UTRs of GABBR1 gene. For rat genes: MT 3′-UTR of GABBR1 gene: 5′-336-AUUUCAGCAGCAGGGCAGAAGGU-358-3′ and 5′-833-AGCCUUGUCCUGUCUAGAAGGUG-855-3′. All constructs were sequence verified. The underlined nucleotides indicate the bases where mutations were made, and the numbers before and after the sequences indicate the positions in GABBR1 gene.
Cell Culture
HEK293 cells 38 (American Type Culture Collection, ATCC, Manassas, VA) and NG108 hybrid (neuroblastoma glioma) cells 39, 40 (American Type Culture Collection, ATCC, Manassas, VA) were cultured with PVN MicroRNA in Sympathoexcitation standard techniques. The ability of miR-7b to reduce GABBR1 expression was studied using a luciferase reporter activity assay in HEK293 cells. The luciferase assay and transfection procedures in HEK293 cells were performed as described previously. 38 NG108 cells were used to study the effect of miR-7b on GABBR1 by using doses of agomiR-7b (50 nmol/L) and antagomiR-7b (100 nmol/L) before Western blot. In separate experiments, Western blot for GABBR1 was done in control cells and cells treated with either NC-agomiR-7b (50 nmol/L), agomiR-7b (50 nmol/L), or agomiR-7b (50 nmol/L) and antagomiR-7b (100 nmol/L) in combination. Further, NG108 cells were treated with ANG II (100 μM) 39 or the combination of ANG II (100 μM) and Los (1 μM) to study the direct effects on HoxD10 and GABBR1 protein expression with Western blot, as well as real-time polymerase chain reaction quantification of miR-7b.
Finally, the role of HoxD10 in the regulation expression of miR-7b and GABBR1 was studied using siRNA knockdown in NG108 cells after treatment with ANG II (100 μM) and the combination of ANG II (100 μM) and Los (1 μM). siRNA targeting HoxD10 and its negative control were purchased from Santa Cruze Inc (CA, USA).
Data Analysis
Group data are expressed as mean±SEM. Group differences in the data was tested using 2-way analysis of variance followed by comparison for individual group differences using the Tukey's test or 1-way analysis of variance followed by Dunnett's test where appropriate. The statistical model for the 2-way analysis of variance used Sham and CHF as one dimension and treatment groups as the other or ANG II and Los as dimensions in those experiments. Statistical significance was indicated by P<0.05. All analyses were performed using GraphPad Prism 5.0.
Results

Development of Heart Failure
Coronary artery ligation caused an average infarct area of 37.4±2.1% ( Table I in the Data Supplement), and 90% of infarcts were transmural, whereas no infarcts were identified in Sham. Pleural fluid and ascites were found in CHF but not (Table  I and II in the Data Supplement). CHF rats had increased LVEDP, the right ventricle (RV)/body weight (BW), and lung/ BW ratio, whereas LVSP and ±dP/dt max were significantly decreased (P<0.05). Heart weight was higher in CHF than in Sham. MAP and HR were not affected by either CHF or Veh infusion into the PVN (Table III in the Data Supplement). CHF rats had higher RSNA and plasma NE ( Figure 1A and 1E), which correlated with a higher PVN Fra-LI activity than untreated Sham (Figure 2A and 2B ).
MiRNA Treatment In Vivo
Infusion of agomiR-7b into the PVN produced CHF-like changes with increased left ventricular diameters and reduced EF and FS (P<0.05) and exacerbated the changes seen in CHF. In addition, both Sham and CHF had higher LVEDP, RV/BW, and lung/BW ratio (P<0.05), whereas LVSP and ±dP/dt max were significantly decreased after agomiR-7b compared with artificial cerebrospinal fluid-treated Sham and CHF (P<0.05). The cardiac effects of agomiR-7b were more pronounced in CHF (Table IV and 
MiRNA Inhibition In Vivo
AntagomiR-7b attenuated the increase in left ventricle dimension and the deterioration of left ventricular performance as indicated by increased EF and FS ( Table II in the Data Supplement) and improved cardiac function by decreasing LVEDP, increasing LVSP, +dP/dt max , and -dP/dt max in CHF animals as well as in agomiR-7b-treated Sham and CHF (P<0.05; Table  IV in the Data Supplement). AntagomiR-7b improved RV/ BW and lung/BW ratios in both CHF and agomiR-7b-treated Sham and CHF animals (Table V in the Data Supplement). Neither artificial cerebrospinal fluid nor NC agomiR-7b affected echocardiographic or hemodynamic parameters in CHF or Sham (Table II , IV, and V in the Data Supplement).
AntagomiR-7b was able to reduce MAP, HR, and RSNA in both Sham and CHF. As with agomiR-7b, the responses were stronger in CHF ( Figure 1A -1D and 1F). Further, the increase in plasma NE in CHF could be inhibited with PVN antagomiR-7b ( Figure 1E) , and Fra-LI activity in the PVN could be reduced (Figure 2A and 2B) . Subcutaneous administration of antagomiR-7b did not affect sympathetic signaling as indicated by RSNA, plasma NE, or Fra-LI activity in the PVN (data not shown).
Identification of Infusion Sites of Fluorescence-Labeled FAM AgomiR-7b and AntagomiR-7b
Histological analysis showed that agomiR-7b and antagomiR-7b-positive cells were localized in the parvicellular and magnocellular divisions of the PVN ( Figure IA in the Data Supplement). No obvious agomiR-7b and antagomiR-7b-positive cell was found in the adjacent brain regions or other areas throughout the brain in most of the rats ( Figure IB in the Data Supplement).
Molecular Regulation of GABBR1 by miR-7b In Vivo
miR-7b was significantly upregulated in PVN of CHF compared with Sham rats ( Figure 3A) . miR-7b can bind to the GABBR1 gene 3′-UTR based on computational and bioinformatics analysis using TargetScan (Wellcome Trust Sanger Institute; Figure 3B ).
Western blot revealed that downregulation of GABBR1 in PVN of CHF when compared with Sham rats (P<0.05, Figure 3C ). There was no change in the supraoptic nucleus ( Figure 3C ). When the luciferase vector carrying the 3′-UTR of GABBR1 was cotransfected with agomiR-7b or ANG II, respectively, luciferase activity was robustly diminished compared with transfection of a scrambled miRNA or Veh. The inhibitory effect of agomiR-7b was antagonized by its antisense antagomiR-7b. On the other hand, agomiR-7b did not suppress translation of luciferase transcripts containing the mutant GABBR1 gene 3′-UTR ( Figure 3D ). Further, Western blot showed lower GABBR1 levels in the PVN of CHF rats ( Figure 4A ) and transfection of agomiR-7b in the NG108 cells, respectively ( Figure 4B ), and infusion in vivo or transfection in vitro of antagomiR-7b prevented this decrease in vivo ( Figure 4A ) or in vitro ( Figure 4B ), respectively. Immunofluorescence showed that CHF rats had fewer GABBR1-positive neurons in the PVN than in the Sham (Figure 4C and 4D) . The reduction was exacerbated by agomiR-7b and alleviated by antagomiR-7b. However, GABBR1 mRNA levels were unchanged by agomiR-7b in both CHF and Sham ( Figure IIA 
Knockdown of AT 1 R in PVN In Vivo
To investigate the cardiovascular consequences of myocardial infarction (MI)-induced AT 1 R upregulation in PVN, we measured the effects of PVN-targeted Ad-siAT 1 R on echocardiographic and LV hemodynamic end points in rat 6 weeks after MI or sham surgery. High-resolution ultrasonographic analysis demonstrated normal cardiac function in Sham+Ad-siGFP animals as evidenced by unaltered EF and FS compared with Sham+Ad-siAT 1 R (Table VI in the Data Supplement). In contrast, a marked decrease in EF and FS was observed in rats that underwent MI surgery ( Table VI in the Data Supplement) . Importantly, Ad-siAT 1 R microinfused into PVN led to significant improvement in lung/BW, RV/BW, left ventricular diastolic and systolic diameter, LVEDP, dp/dt, EF, FS, and basal RSNA in MI-treated animals, whereas the Sham+Ad-siGFP did not alter either parameter (Table VI in the Data Supplement).
HoxD10 Gene Transfer In Vivo
Compared with Sham-null rats, the lung/BW, RV/BW, left ventricular diastolic and systolic diameter, LVEDP, and basal RSNA increased, whereas the dp/dt, FS, and EF decreased in CHFnull rats. These changes caused by the MI were significantly enhanced by Ad-HoxD10 (Table VII in 
ANG II-Induced Sympathoexcitation Is Rescued by Antagomir-7b
Rats treated with PVN ANG II+NC antagomiR-7b had increased HR, MAP, RSNA, and plasma NE compared with those of rats treated with PVN NC antagomiR-7b ( 
ANG II-Induced Sympathoexcitation Is Enhanced by Silencing of GABBR1
Rats treated with PVN ANG II+Ad-siGFP had increased HR, MAP, RSNA, and plasma NE compared with those of rats 
Effects of In Vivo Knockdown Silencing of AT 1 R in the PVN on HoxD10, GABBR1 Protein Expression, and miR-7b mRNA Expression
Role of HoxD10 in miR-7b Regulation and GABBR1 Expression In Vivo
HoxD10 protein expression in the PVN was increased in CHF rats and normalized by Los treatment (Figure 5A ). This was associated with similar changes in miR-7b ( Figure 5C ) and a decrease in GABBR1 ( Figure 5B ). HoxD10 protein expression in the PVN was increased in CHF+Ad-null rats and enhanced by gene transferring of HoxD10 ( Figure VA 
Molecular Regulation of GABBR1 by miR-7b and HoxD10 In Vitro
Transfection of agomiR-7b reduced the protein expression of GABBR1 in the PVN ( Figure 4A ) and in cultured NG108 cells ( Figure 4B ). This effect was abolished by cotransfection of antagomiR-7b ( Figure 4A and 4B) . AgomiR-7b did not affect GABBR1 mRNA levels in NG108 cells ( Figure IIB in the Data Supplement). ANG II (100 µmol/L) increased the expression of HoxD10 protein and miR-7b mRNA expression ( Figure 6A and  6C) , decreased the expression of GABBR1 protein in NG108 cells ( Figure 6B ), and pretreatment with Los or silencing of HoxD10 using siRNA (HoxD10 siRNA, siHoxD10) ameliorated the effect in NG108 cells ( Figure 6A-6C ), but the siHoxD10 negative control oligonucleotides did not (data not shown).
ANG II-Induced Downregulation of GABBR1 Is Rescued by Antagomir-7b
Infusion of ANG II into the PVN downregulated GABBR1 expression ( Figure 7) . Infusion of antagomiR-7b prevented this downregulation. There were no significant differences between NC antagomiR-7b and antagomiR-7b groups (Figure 7 ).
Discussion
The main finding in this study was the demonstration of an ANG II/AT 1 R/HoxD10/miR-7b/GABBR1 signaling pathway, localized to the PVN, regulating sympathoexcitation, and playing a pathogenic role in CHF. Thereby, the present study provides a molecular mechanism for the well-known effect of ANG II on sympathoexcitation in the hypothalamus.
The present result that long-term RSNA is regulated through protein expression effects of miRNA that is stimulated by a specific transcription factor activation by ANG II stimulation of AT 1 R in the PVN is important because sympathetic nerves directly innervate the distal renal tubule and have a significant influence on sodium balance. 41 Increased renal sympathetic nerve stimulation is a major mechanism for salt and water retention in patients with circulatory failure. 1, 41, 42 Fluid retention in CHF, although necessary to increase preload and maintain cardiac output, leads to venous congestion and potentially decompensation. 1, 43 Our observations demonstrate that the activity of ANG II and AT 1 R in the PVN may play a substantial role in the sympathetic stimulation associated with CHF.
We found that CHF increased the expression of HoxD10 protein and miR-7b, whereas the expression of GABBR1 protein was decreased in the PVN. In turn, there were larger effects of infusion of both sense and antisense miR-7b in rats with CHF when compared with Sham. These findings indicate that the ANG II/AT 1 R/HoxD10/miR-7b/GABBR1 signaling cascade plays an important role in the stimulation of the sympathetic system characteristic of heart failure.
The in vivo findings were reproduced in NG108 cells where an enhanced expression of HoxD10 was found after ANG II treatment, a change that could be inhibited by Los or by transfection with a HoxD10 silencer. These results support our findings of miR-7b inhibition of GABBR1 translation in the PVN, an important mechanism for ANG II-induced sympathoexcitation, and confirm that this effect is controlled by HoxD10.
Direct AT 1 R stimulation increased HoxD10 and miR-7b expression in the PVN and decreased GABBR1 expression. AT 1 R blockade prevented the ANG II-induced changes of HoxD10, miR-7b, and GABBR1. Furthermore, AT 1 R silencing by using siRNA inhibited the CHF-induced increase of HoxD10, and miR-7b, at the same time, rescued the CHFinduced decrease of GABBR1. This is a novel finding that increase our understanding of the molecular mechanisms driving enhanced sympathetic activity during CHF.
The effect of HoxD10 on the miR-7 promoter and miR-7 expression has been previously reported. 23 The present data reveals, for the first time, that binding of HoxD10 to the miR-7b promoter is important for the ANG II-mediated miR-7b activation in the central nervous system and the PVN. This finding is supported by our observations that transfection with HoxD10 silencer in ANG II-treated NG108 cells reversed the upregulation of miR-7b nearly back to the control level.
The discovery of HoxD10 and miR-7b expression in the PVN and their regulation by AT 1 R activation during CHF are new findings of importance in cardiovascular physiology and for the pathophysiology of CHF. Further, the expression of miR-7b in PVN and its important role in the regulation of sympathoexcitation through the regulation of GABBR1 translation is an important new finding that improves our understanding of how excessive AT 1 R stimulation may drive long-time effects on sympathetic signaling.
The specificity of the present results was demonstrated using infusions of scrambled miRNA and by peripheral administration of both agonist and antagonist oligonucleotides. Interestingly, the effect of miR-7b on GABBR1 seems to be primarily on the translational level as indicated by changes in GABBR1 protein expression with little effect on mRNA levels, in vivo and in vitro. These observations suggest that after AT 1 R stimulation and during CHF, the GABBR1 protein is downregulated not by mRNA degradation by miR-7b, but by post-transcriptional regulation. The situation is further complicated by the failure of AT 1 R silencing in vivo to normalize GABBR1 expression, even though it reduced the activation of HoxD10 and miR-7b.
Sympathetic signaling in CHF is known to be differentiated, with marked increased signaling to the kidneys and the heart, whereas other organs are not as strongly modulated. 44 Although we have strong indications that cardiac and vascular sympathetic nerve activity is regulated by the ANG II/AT 1 R/ HoxD10/miR-7b/GABBR1 pathway, as measured using HR and MAP, the present data leave unanswered whether the mechanism is important for the differentiation of sympathetic activity between different organs.
In this study, CHF was produced by coronary ligation, which is a commonly used model of MI. Cardiac function and compensatory hypertrophy is related to time after ligation and infarct area and were verified in the present project using both cardiac histology, echocardiography, and invasive measurement of cardiac function.
In conclusion, in the PVN, ANG II, by AT 1 R stimulation, enhances sympathetic activity by activating HoxD10, which increases miR-7b expression and thereby reduces GABBR1 translation. ANG II-induced HoxD10 activation via a miRNAmediated pathway is a new finding partially clarifying the role of the brain Renin Angiotensin System in cardiovascular regulation. These observations open an interesting area for further study.
